Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Bought by Fort Sheridan Advisors LLC

Fort Sheridan Advisors LLC raised its holdings in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 71.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 55,177 shares of the company’s stock after purchasing an additional 23,000 shares during the period. Fort Sheridan Advisors LLC’s holdings in Lineage Cell Therapeutics were worth $28,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in LCTX. Defender Capital LLC. raised its position in shares of Lineage Cell Therapeutics by 19.2% in the 4th quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock valued at $2,997,000 after purchasing an additional 961,150 shares during the last quarter. Geode Capital Management LLC increased its stake in Lineage Cell Therapeutics by 2.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock valued at $3,331,000 after purchasing an additional 83,274 shares in the last quarter. Barclays PLC raised its holdings in shares of Lineage Cell Therapeutics by 311.3% in the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after buying an additional 159,924 shares during the last quarter. State Street Corp lifted its stake in shares of Lineage Cell Therapeutics by 1.8% during the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock worth $2,361,000 after buying an additional 45,483 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of Lineage Cell Therapeutics by 35.5% during the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after buying an additional 18,053 shares during the last quarter. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX opened at $0.56 on Friday. The stock has a market cap of $123.77 million, a price-to-earnings ratio of -4.68 and a beta of 1.21. Lineage Cell Therapeutics, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $1.61.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on LCTX shares. D. Boral Capital reduced their target price on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. Maxim Group decreased their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Friday, January 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a research report on Tuesday, February 11th.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.